By Zeke Miller and Darlene Superville 

Updated 6:10 pm ET

President Donald Trump said Monday that he is taking a malaria drug to protect against the new coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.

Trump told reporters he has been taking the drug, hydroxychloroquine, and a zinc supplement daily “for about a week and a half now.” Trump spent weeks pushing the drug as a potential cure or prophylaxis for COVID-19 against the cautionary advice of many of his administration's top medical professionals. The drug has the potential to cause significant side effects in some patients and has not been shown to combat the new coronavirus.

Trump said his doctor did not recommend the drug to him, but he requested it from the White House physician.

"I started taking it, because I think it’s good," Trump said. "I’ve heard a lot of good stories.”

The Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings, due to sometimes fatal side effects. Regulators issued the alert for the drug, which can also be used to treat lupus and arthritis, after receiving reports of heart-rhythm problems, including deaths, from poison control centers and other health providers.

Trump dismissed reports of side effects, saying, “All I can tell you is, so far I seem to be OK.”

At least two White House staffers tested positive for COVID-19 earlier this month, sparking concerns about the steps taken by the administration to protect the president and sending Vice President Mike Pence and other officials into varying forms of self-isolation.

The White House has since mandated that those in the West Wing wear face coverings and has introduced daily testing for the virus for the president, vice president, and those they come in close contact with.

Trump last underwent an “interim” checkup in a November visit to Walter Reed National Military Medical Center that was not noted on his public schedule. His last complete physical took place in February 2019.

Trump has repeatedly pushed the use of the drug with or without the antibiotic azithromycin, but no large, rigorous studies have found them safe or effective for preventing or treating COVID-19.

Two large observational studies, each involving around 1,400 patients in New York, recently found no benefit from hydroxychloroquine. Two new ones published Thursday in the medical journal BMJ reached the same conclusion.

One, by French researchers, gave 84 hospitalized patients the drug and 97 others the usual care. There were no differences in the odds of death, need for intensive care or developing severe illness.

The other study from China was a stricter test: 150 adults hospitalized with mild or moderate illness were randomly assigned to get hydroxychloroquine or usual care. The drug made no difference in rates of clearing the virus or time to relief of symptoms, and they brought more side effects.

In April, the National Institutes of Health launched a study testing hydroxychloroquine versus a placebo drug in 500 hospitalized COVID-19 patients. Last week, NIH announced another study to see if hydroxychloroquine plus azithromycin can prevent hospitalization or death in people with mild to moderate illness. About 2,000 U.S. adults with confirmed coronavirus infections and symptoms such as fever, cough, or shortness of breath will get the drugs or placebo pills.

U.S. prescriptions for hydroxychloroquine surged roughly 80% in March to more than 830,000 compared with the same period in the prior year, according to data tracking firm IQVIA. That jump in prescribing came before the federal government accepted nearly 30 million doses of the drug donated to the strategic national stockpile by foreign drugmakers. Since then, millions of those tablets have been shipped to U.S. hospitals nationwide for use treating patients with COVID-19.

—-

AP medical writers Marilynn Marchione in Milwaukee and Matthew Perrone in Washington contributed to this report.

Share:
More In Politics
Behind the Sandy Hook Settlement With Gun Maker Remington
Almost a decade after facing a parent's worst nightmare, the families of the young students killed in the Sandy Hook School shooting reached a settlement with gun manufacturer Remington, makers of the Bushmaster AR-15 used in the crime. David Pucino, deputy chief counsel, Giffords Law Center to Prevent Gun Violence joined Cheddar News to discuss the families' case and how its strategy brought about the legal settlement. "They built a really great case showing the way that Bushmaster developed its advertising to drive sales using those toxic messages.
Western Drought Worst In 1,200 Years
A new analysis reveals that for more than two decades, the West has been the driest it has ever been since 800 A.D. The drought which began in 2000 has brought more devastating wildfires and draining water reserves well below healthy levels. Climate Scientists and Adjunct Associate Research Scientist at Lamont Doherty Earth Observatory at Columbia University,Benjamin Cook, joined Cheddar to discuss more.
Economist Sees Six Rate Hikes in 2022 After High January PPI Number
Inflation remains hot as the January PPI has increased by 1 percent, twice what analysts had been expecting with a jump of 9.7 over the year. Beth Ann Bovino, the U.S. chief economist, for S&P Global Ratings, joined Cheddar News to discuss the rapid pace of inflation alongside higher wages, predicting the Federal Reserve will act quickly and forcefully this year. "They haven't changed their forecast, yet, that's gonna come out soon. But we expect that a March rate hike is basically pretty much baked in the cake," she said. "We think six rate hikes in total for 2022."
U.S Chamber of Commerce Hosts Virtual Event 'Developing the Black-Owned Business Ecosystem'
For black history month, Cheddar is highlighting black business leaders who are driving the need for representation forward. On February 10, the U.S. Chamber of Commerce hosted an event called 'Developing the Black-Owned Business Ecosystem.' The virtual event was organized under the lobbying group's two initiatives -- the Equality of Opportunity Initiative, and the Coalition to Back Black Businesses. The event highlighted the developments needed to develop more black-owned businesses in the U.S. Dr. Anthony Wilbon, Dean of the School of Business at Howard University, joined Cheddar News' Closing Bell to discuss his experience as a speaker at the event.
Two Democratic Senators Allege Secret CIA Spying On Americans
A newly declassified letter by senators Ron Wyden and Martin Heinrich claimed the CIA. has been conducting a Secret Surveillance Program which has been collecting a bulk of data from American citizens. The letter which was written in April of 2021 urges the CIA to come clean about the kind of data it collects and how many Americans have been impacted. According to these two senators, the program did not have the safeguards of congressional oversight.
Stocks Close Lower to Begin Week as Russia-Ukraine Tensions Weigh on Sentiment
Art Hogan, Chief Market Strategist at National Securities, joined Cheddar News' Closing Bell, where he says investors are taking a wait-and-see approach when it comes to the situation between Russia and the Ukraine and elaborates on the impact higher oil prices stemming from the conflict would have on the market.
Behind Lawmaker Concerns Over Possible CIA Data Collection on Americans
Last week, Senators Ron Wyden of Oregon and Martin Heinrich of New Mexico, Democrats on the Senate Intelligence Committee, wrote a a letter airing concerns that the CIA is collecting the data of American citizens without their consent. The lawmakers fear that the program might be exploiting private data. Morgan Wright, the chief security advisor at cybersecurity firm SentinelOne, joined Cheddar News to discuss the ramifications of the letter. "We don't have all the dots in one place to connect them," said Wright, cautioning against jumping to conclusions.
Load More